HC Wainwright Issues Positive Estimate for KYTX Earnings

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) – Analysts at HC Wainwright raised their Q3 2026 earnings per share (EPS) estimates for shares of Kyverna Therapeutics in a research report issued on Wednesday, August 12th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($0.66) per share for the quarter, up from their prior estimate of ($0.78). HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($2.78) per share. HC Wainwright also issued estimates for Kyverna Therapeutics’ Q4 2026 earnings at ($0.75) EPS, FY2026 earnings at ($2.70) EPS, Q1 2027 earnings at ($0.78) EPS, Q2 2027 earnings at ($0.74) EPS, Q3 2027 earnings at ($0.74) EPS, Q4 2027 earnings at ($0.54) EPS and FY2027 earnings at ($2.79) EPS.

KYTX has been the topic of a number of other reports. JPMorgan Chase & Co. reduced their target price on shares of Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a report on Wednesday, May 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kyverna Therapeutics in a research note on Wednesday, June 24th. Finally, Wall Street Zen cut shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Kyverna Therapeutics has an average rating of “Moderate Buy” and an average target price of $30.00.

Kyverna Therapeutics Trading Up 0.4%

Kyverna Therapeutics stock opened at $8.08 on Friday. The stock has a market cap of $499.67 million, a PE ratio of -2.75 and a beta of 1.93. The stock has a 50-day moving average price of $8.06 and a 200 day moving average price of $8.44. Kyverna Therapeutics has a 52 week low of $3.27 and a 52 week high of $13.67. The company has a current ratio of 8.15, a quick ratio of 8.15 and a debt-to-equity ratio of 0.13.

Kyverna Therapeutics (NASDAQ:KYTX) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.05.

Hedge Funds Weigh In On Kyverna Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Public Employees Retirement System of Ohio purchased a new stake in shares of Kyverna Therapeutics during the 3rd quarter worth about $28,000. Federated Hermes Inc. lifted its position in Kyverna Therapeutics by 36.6% during the fourth quarter. Federated Hermes Inc. now owns 20,705 shares of the company’s stock valued at $195,000 after buying an additional 5,547 shares in the last quarter. Rhumbline Advisers lifted its position in Kyverna Therapeutics by 22.0% during the first quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock valued at $61,000 after buying an additional 5,694 shares in the last quarter. Bank of America Corp DE grew its stake in Kyverna Therapeutics by 41.6% during the fourth quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock worth $81,000 after buying an additional 6,400 shares during the period. Finally, Vanguard Group Inc. increased its position in shares of Kyverna Therapeutics by 0.8% in the third quarter. Vanguard Group Inc. now owns 1,322,625 shares of the company’s stock worth $7,936,000 after acquiring an additional 9,858 shares in the last quarter. 18.08% of the stock is owned by institutional investors and hedge funds.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical?stage biotechnology company dedicated to developing engineered regulatory T?cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen?specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.